SMARCB1 and embryonal neoplasm: The WHO 2016 classification scheme also introduced major changes in the classification of embryonal tumors—medulloblastomas were separated into four molecular subtypes based on WNT, SHH, and TP53 statuses; SMARCB1/SMARCA4 loss was introduced as a necessary criterion for the diagnosis of atypical teratoid/rhabdoid tumor; and embryonal tumors with multilayered rosettes with C19MC amplifications was introduced as its own diagnostic category [5,8].